Non-GLP-1 Self-Injection Devices Market
完整報告名稱與涵蓋範圍
Non-GLP-1 Self-Injection Devices Market Size, Share & Trends Analysis Report, By Device Type (Prefilled Syringes with Safety Systems, Autoinjectors, Pen Injectors, Wearable and On-Body Injectors, Needle-Free and Emerging Injectors), By Therapeutic Area (Immunology and Autoimmune Diseases, Neurology (Migraine, Multiple Sclerosis), Oncology Supportive Care and Hematology, Endocrine, Fertility and Rare Diseases, Cardiovascular and Other Chronic Therapies), By Usability (Disposable Devices, Reusable Devices), By End User, By Region, and Segment Forecasts, 2026-2035
報告摘要
The non-GLP-1 self-injection devices market covers prefilled syringes with safety systems, autoinjectors, pen injectors, wearable injectors and needle-free devices used for patient self-administration of injectable therapies outside the incretin and insulin categories, spanning immunology, neurology, oncology supportive care, endocrine, rare disease and cardiovascular therapies. Incretin and insulin pens and autoinjectors are excluded and are addressed in dedicated InsightAce studies, allowing this analysis to isolate the diversified biologics and specialty injectable device pool that has been overshadowed by GLP-1 demand.
Growth is driven by the steady conversion of biologics and specialty therapies to subcutaneous self-administration, by biosimilar launches that require device platforms with established regulatory histories, by lifecycle strategies that pair reformulations with improved devices and by payer and provider preference for home treatment. Device makers compete on human factors, injection time for viscous formulations, safety and needle-shielding, connectivity and sustainability, while pharmaceutical companies increasingly demand platform flexibility across dose volumes and containers. The concentration of incretin demand on device manufacturers has created capacity and prioritisation tension for other therapies, which the study analyses explicitly.
North America and Europe lead demand, with Japan, China and India expanding through biosimilars and domestic biologics. Competition involves drug delivery platform companies, pharmaceutical packaging and container groups and medical device contract manufacturers.
The InsightAce study supplies US$ forecasts for all device type, therapeutic area, usability and end user and regional segments over 2026-2035, segment-level trend analysis, competitive landscape assessment and profiling of the leading companies.
授權報價
| Single User | $4,500 USD |
| Enterprise / Global Site Licence | $9,500 USD |
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Non-GLP-1 Self-Injection Devices Market Snapshot
Chapter 4. Global Non-GLP-1 Self-Injection Devices Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Market Drivers
4.3. Market Challenges
4.4. Emerging Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis - Porter's Five Forces Analysis
4.7. Competitive Landscape and Market Positioning
4.8. Market Opportunity Analysis
Chapter 5. Market Segmentation 1: By Device Type Estimates & Trend Analysis
5.1. Device Type & Market Share, 2026 & 2035
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Device Type:
5.2.1. Prefilled Syringes with Safety Systems
5.2.2. Autoinjectors
5.2.3. Pen Injectors
5.2.4. Wearable and On-Body Injectors
5.2.5. Needle-Free and Emerging Injectors
Chapter 6. Market Segmentation 2: By Therapeutic Area Estimates & Trend Analysis
6.1. Therapeutic Area & Market Share, 2026 & 2035
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Therapeutic Area:
6.2.1. Immunology and Autoimmune Diseases
6.2.2. Neurology (Migraine, Multiple Sclerosis)
6.2.3. Oncology Supportive Care and Hematology
6.2.4. Endocrine, Fertility and Rare Diseases
6.2.5. Cardiovascular and Other Chronic Therapies
Chapter 7. Market Segmentation 3: By Usability Estimates & Trend Analysis
7.1. Usability & Market Share, 2026 & 2035
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Usability:
7.2.1. Disposable Devices
7.2.2. Reusable Devices
Chapter 8. Market Segmentation 4: By End User Estimates & Trend Analysis
8.1. End User & Market Share, 2026 & 2035
8.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by End User:
8.2.1. Pharmaceutical and Biotechnology Companies
8.2.2. Home Users and Patients
8.2.3. Hospitals and Clinics
Chapter 9. Non-GLP-1 Self-Injection Devices Market: Regional Estimates & Trend Analysis
9.1. North America
9.1.1. United States
9.1.2. Canada
9.2. Europe
9.2.1. Germany
9.2.2. United Kingdom
9.2.3. France
9.2.4. Italy
9.2.5. Spain
9.2.6. Rest of Europe
9.3. Asia Pacific
9.3.1. China
9.3.2. Japan
9.3.3. India
9.3.4. South Korea
9.3.5. Australia
9.3.6. Southeast Asia
9.3.7. Rest of Asia Pacific
9.4. Latin America
9.4.1. Brazil
9.4.2. Mexico
9.4.3. Rest of Latin America
9.5. Middle East & Africa
9.5.1. GCC Countries
9.5.2. South Africa
9.5.3. Rest of Middle East & Africa
Chapter 10. Competitive Landscape
10.1. Company Market Positioning Analysis
10.2. Strategic Developments (Partnerships, Expansions, Product Launches, M&A)
Chapter 11. Company Profiles
11.1. West Pharmaceutical Services, Inc.
11.2. Becton, Dickinson and Company
11.3. Ypsomed AG
11.4. SHL Medical AG
11.5. Owen Mumford Ltd.
11.6. Gerresheimer AG
11.7. Stevanato Group S.p.A.
11.8. Nemera
11.9. Phillips-Medisize (Molex, Koch Industries)
11.10. Haselmeier (medmix AG)
11.11. Antares Pharma (Halozyme Therapeutics, Inc.)
11.12. Enable Injections, Inc.
11.13. Schott Pharma AG & Co. KGaA
11.14. Terumo Corporation
11.15. Credence MedSystems, Inc.
圖表清單 List of Tables & Figures
Table 1. Global Non-GLP-1 Self-Injection Devices Market Revenue Forecast by Device Type, 2026-2035 (US$ Mn)
Figure 1. Global Non-GLP-1 Self-Injection Devices Market Segmentation and Scope Overview
Table 2. Global Non-GLP-1 Self-Injection Devices Market Revenue Forecast by Therapeutic Area, 2026-2035 (US$ Mn)
Figure 2. Global Non-GLP-1 Self-Injection Devices Market Share by Device Type, 2026 & 2035
Table 3. Global Non-GLP-1 Self-Injection Devices Market Revenue Forecast by Usability, 2026-2035 (US$ Mn)
Figure 3. Self-Injection Device Demand by Therapeutic Area Excluding Incretin and Insulin Products, 2026-2035
Table 4. Global Non-GLP-1 Self-Injection Devices Market Revenue Forecast by End User, 2026-2035 (US$ Mn)
Figure 4. Device Capacity Prioritisation Effects of Incretin Demand on Other Therapy Programs
Table 5. Global Non-GLP-1 Self-Injection Devices Market Revenue Forecast by Region, 2026-2035 (US$ Mn)
Figure 5. Asia Pacific Non-GLP-1 Self-Injection Devices Growth Opportunity Analysis
Table 6. North America Non-GLP-1 Self-Injection Devices Market Revenue by Country, 2026-2035 (US$ Mn)
Figure 6. Competitive Positioning of Key Non-GLP-1 Self-Injection Devices Market Participants
Table 7. Europe Non-GLP-1 Self-Injection Devices Market Revenue by Country, 2026-2035 (US$ Mn)
Figure 7. Porter's Five Forces Analysis of the Global Non-GLP-1 Self-Injection Devices Market
Table 8. Asia Pacific Non-GLP-1 Self-Injection Devices Market Revenue by Country, 2026-2035 (US$ Mn)
Figure 8. Biosimilar Device Platform Selection and Interchangeability Considerations
Table 9. Strategic Developments of Leading Non-GLP-1 Self-Injection Devices Market Participants, 2023-2026
提及公司
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們